FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries (collectively referred to as "Henlius"), has received approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX97, a small molecule inhibitor targeting KAT6A/B, for the treatment of advanced or metastatic solid tumors. Henlius plans to initiate related clinical studies in China once the necessary conditions are met.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments